Europe Analysis

Pages

Industry Trend Analysis - Generic Competition To Continue To Hurt AstraZeneca Revenues - JUNE 2017

AstraZeneca's shareholders will keep a close eye on the company's management's strategy, the late-stage R&D pipeline and newly launched USD1.1bn cost-cutting plan. While investor focus on company activity has been strong since the decline in sales of the company's top blockbuster drugs - Nexium lost patent protection in the US in February 2015 and Crestor experienced patent expiry in...

READ FULL ARTICLE

Industry Trend Analysis - High Generic Medicine Growth Potential In Central & Eastern Europe - MAY 2017

The growing pressure on healthcare payers across Europe will lead to an outperformance of generic medicine sales with respect to the wider market. The Western Europe generic market will remain significantly larger in value terms over our forecast period; however, the Central and Eastern European market represents higher sales potential given the emphasis on the expansion of healthcare acce...

READ FULL ARTICLE

Pages